Bamco Inc. NY Sells 150,693 Shares of Icon Plc $ICLR

Bamco Inc. NY trimmed its holdings in shares of Icon Plc (NASDAQ:ICLR) by 22.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 534,248 shares of the medical research company’s stock after selling 150,693 shares during the quarter. Bamco Inc. NY owned approximately 0.66% of Icon worth $97,351,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ICLR. Guggenheim Capital LLC purchased a new position in shares of Icon in the 4th quarter valued at $244,000. AQR Capital Management LLC purchased a new stake in shares of Icon during the 4th quarter worth $308,000. Harris Associates L P boosted its position in Icon by 7.2% during the fourth quarter. Harris Associates L P now owns 2,510,166 shares of the medical research company’s stock valued at $457,402,000 after purchasing an additional 167,607 shares in the last quarter. Braidwell LP purchased a new position in Icon in the fourth quarter valued at about $13,369,000. Finally, EFG International AG purchased a new position in Icon in the fourth quarter valued at about $27,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Piper Sandler downgraded Icon to a “neutral” rating in a research report on Thursday, May 28th. Jefferies Financial Group reiterated a “buy” rating and set a $165.00 price objective on shares of Icon in a research note on Friday, May 29th. Weiss Ratings lowered shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. Truist Financial upped their target price on Icon from $139.00 to $159.00 and gave the company a “hold” rating in a research report on Friday, May 29th. Finally, Barclays raised their target price on Icon from $120.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Friday, May 29th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $156.44.

Icon Stock Down 0.2%

NASDAQ:ICLR opened at $143.27 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.10 and a quick ratio of 1.10. The company’s fifty day moving average price is $123.69 and its 200-day moving average price is $139.54. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The firm has a market capitalization of $10.97 billion, a P/E ratio of 23.26, a PEG ratio of 11.34 and a beta of 1.26.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, June 17th. The medical research company reported $2.52 EPS for the quarter, beating the consensus estimate of $2.47 by $0.05. The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $1.99 billion. Icon had a net margin of 5.98% and a return on equity of 9.50%. The firm’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.43 earnings per share. As a group, equities research analysts anticipate that Icon Plc will post 9.74 EPS for the current year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.